| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790046 | Urologic Oncology: Seminars and Original Investigations | 2018 | 7 Pages |
Abstract
High CXCR1 expression indicates reduced benefit from TKIs therapy in patients with mRCC. The mechanism may be attributed to the enriched pathways of hypoxia and angiogenesis in CXCR1 positive patients. CXCR1 may be a potential therapeutic target for mRCC, but further studies are required.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Xiang M.D., Li M.D., Jiajun M.D., Zhiyuan M.D., Ying M.D., Yang M.D., Zewei M.D., Yuanfeng M.D., Jianming M.D., Jiejie Ph.D.,